drugset / Trial / NCT00413946

Does Erythropoietin Improve Outcome in Very Preterm Infants?

NCT00413946

RandomizedParallel-groupQuadruple-blindPrevention

Summary

The main goal of this trial is to investigate whether early administration of human erythropoietin (EPO) in very preterm infants improves neurodevelopmental outcome at 24 months corrected age. This study is designed as randomized, double-masked, placebo controlled multicenter study involving at least 420 patients.

Timeline

Start
2006-01
Primary completion
2012-12
Completion
2012-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject epoetin alfa Protein / enzyme biologic 3000 iu/kg